Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07182149 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Normunity AccelCo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT07182149: Recruiting Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Normunity AccelCo.
NCT07182149 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Normunity AccelCo. The registered enrollment target is 150 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07182149, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Normunity AccelCo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Primary Outcome
Number of participants who experience treatment emergent AEs or SAEs
Conditions Studied
Interventions
- DRUG NRM-823
Study Locations (9)
Texas
- Normunity Investigational Site - Dallas
- Normunity Investigational Site - San Antonio
Colorado
- Normunity Investigational Site - Denver
Connecticut
- Normunity Investigational Site - New Haven
Minnesota
- Normunity Investigational Site - Minneapolis
Ohio
- Normunity Investigational Site - Maumee
Pennsylvania
- Normunity Investigational Site - Philadelphia
Tennessee
- Normunity Investigational Site - Nashville
Virginia
- Normunity Investigational Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 1 |
What NCT07182149 shows while recruiting
NCT07182149 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower).
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NRM-823 is the first listed.
NCT07182149 lists 9 locations in 8 states (Texas, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT07182149 about?
NCT07182149 is a clinical study titled "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors". This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT07182149?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-10-30. Estimated completion is 2028-10-31.
What conditions does trial NCT07182149 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, NSCLC, Gastric Adenocarcinoma.
What interventions are being tested in trial NCT07182149?
The interventions under investigation include: NRM-823 (DRUG).
Who is sponsoring clinical trial NCT07182149?
This trial is sponsored by Normunity AccelCo, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07182149 being conducted?
This trial has 9 study locations across Colorado, Connecticut, Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07182149's enrollment target sits among peer trials
150 120th of 322 higher than 200 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI